Journal
CANCER BIOLOGY & THERAPY
Volume 6, Issue 7, Pages 1015-1017Publisher
LANDES BIOSCIENCE
DOI: 10.4161/cbt.6.7.4338
Keywords
Ecteinascidin-743 (Yondelis); rhabdomyolysis; sarcoma
Categories
Ask authors/readers for more resources
Rhabdomyolysis is a clinical syndrome in which skeletal muscle damage and necrosis leads to the release of intracellular muscle contents, which can ultimately lead to electrolyte disturbances, renal failure and even death. Chemotherapy is an extremely rare cause of rhabdomyolysis. Herein, we describe a fatal case of rhabdomyolysis in a patient with metastatic sarcoma after receiving the chemotherapeutic agent Ecteinascidin-743 (ET-743, trabectedin) as palliative chemotherapy treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available